CordenPharma Plankstadt announced the design and installment of a new manufacturing line dedicated to producing Veterinary Drug Products for 500kg scale batch sizes to supply a complex innovative product for application in the veterinary health market. This new line is part of a production plant that is dedicated to Veterinary Drug Products.
CordenPharma is a full-service CDMO for APIs, Drug Products and Packaging. Services with multiple cGMP facilities across Europe and the US organized under five Technology Platforms – Peptides, Oligonucleotides, Lipids, & Carbohydrates – Injectables – Highly Potent & Oncology – Small Molecules – and Antibiotics.
CordenPharma Plankstadt, located near Heidelberg, Germany, are experts in the development and manufacturing of solid dosage forms, specializing in the safe handling of Highly Potent APIs and Drug Products, with a full range of services from pharmaceutical development for phase I-III to commercial-scale manufacturing, packaging and pharma-logistics.
The expansion of the production capabilities at CordenPharma Plankstadt are the result of a new, long-term custom manufacturing agreement for an animal health application, which the company recently signed. Work will commence in the second quarter of 2017, with a targeted mechanical completion by the 2nd quarter of 2018 and commercial supply for the global launch campaign planned to start in the second half of 2018. CordenPharma Plankstadt has supported the customer over the last year and a half, from initial technology transfer and development activities to the timely manufacturing of registration batches.
“This is an extremely important and significant investment for CordenPharma Plankstadt. This new production line will allow the fully contained handling of highly potent APIs in a dedicated facility for the manufacturing of Veterinary Drug Products. This is a unique opportunity in the industry,” states Frank Hähner, Managing Director of CordenPharma Plankstadt.
“CordenPharma’s goal is to be the leading CDMO for the development and manufacturing of Highly Potent & Oncology solid dosage forms, both now and in the future. This investment greatly contributes to that strategy, while further expanding and strengthening our capabilities and service offerings,” adds Michael Quirmbach, Vice President of Global Marketing & Sales, CordenPharma International.